Title of article
Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up.
Author/Authors
Mirzania، Mehrzad نويسنده Hematology and Medical Oncology Department, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran , , Khalili، Sedigheh نويسنده Arak University of Medical Sciences, Arak, Iran. Khalili, Sedigheh , Hasanpoor، Akbar نويسنده Arak University of Medical Sciences, Arak, Iran. Hasanpoor, Akbar , Shamshiri، Ahmad Reza نويسنده ,
Issue Information
فصلنامه با شماره پیاپی 0 سال 2014
Pages
38
From page
4
To page
41
Abstract
Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patientʹs clinical symptoms and platelet counts improved.
Journal title
International Journal of Hematology-Oncology and Stem Cell Research (IJHOSCR)
Serial Year
2014
Journal title
International Journal of Hematology-Oncology and Stem Cell Research (IJHOSCR)
Record number
2393654
Link To Document